The federal 340B Drug Pricing Program (340B Program) provides qualified health care providers, known as Covered Entities, with the ability to purchase outpatient medications at significant discounts. This program is crucial for safety net providers that serve at-risk patient populations. However, over the years, the 340B Program has become a source of contention among various stakeholders, including Covered Entities, drug manufacturers, and advocacy groups. While Covered Entities argue that the 340B Program is essential for providing affordable care to vulnerable patients, drug manufacturers and some associated groups have raised concerns over program compliance, particularly regarding the use of contract pharmacies and the associated lack of oversight.
Read More: https://340bwell.com/case-studies/340b-program-compliance-in-a-shifting…